Michael G. Kauffman
2021
Compensation breakdown
Non-Equity Incentive Plan | $237,188 |
---|---|
Option Awards | $1,507,217 |
Salary | $474,375 |
Stock Awards | $832,832 |
Other | $17,977 |
Total | $3,069,589 |
Kauffman received $1.5M in option awards, accounting for 49% of the total pay in 2021.
Kauffman also received $237.2K in non-equity incentive plan, $474.4K in salary, $832.8K in stock awards and $18K in other compensation.
Rankings
In 2021, Michael G. Kauffman's compensation ranked 4,338th out of 12,415 executives tracked by ExecPay. In other words, Kauffman earned more than 65.1% of executives.
Classification | Ranking | Percentile |
---|---|---|
All | 4,338 | 65th |
Manufacturing | 1,789 | 68th |
Chemicals And Allied Products | 753 | 68th |
Drugs | 672 | 68th |
Pharmaceutical Preparations | 477 | 69th |
Kauffman's colleagues
We found five more compensation records of executives who worked with Michael G. Kauffman at Karyopharm Therapeutics in 2021.
2021
Richard Paulson
Karyopharm Therapeutics
Chief Executive Officer
2021
Sharon Shacham
Karyopharm Therapeutics
Chief Scientific Officer
2021
Michael Mason
Karyopharm Therapeutics
Chief Financial Officer
2021
Jatin Shah
Karyopharm Therapeutics
Chief Medical Officer
2021
Ran Frenkel
Karyopharm Therapeutics
Executive Vice President, Chief Development Officer
News
April 8, 2022
April 7, 2021
April 9, 2020
April 19, 2019